Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.615 AUD -3.58% Market Closed
Market Cap: 2.1B AUD

EV/FCFF
Enterprise Value to FCFF

-33.7
Current
-14.3
Median
3.7
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-33.7
=
Enterprise Value
2.2B AUD
/
FCFF
-42.7m USD
 
AU
Mesoblast Ltd
ASX:MSB
Average EV/FCFF: 24.8
Negative Multiple: -33.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 712.4
US
Abbvie Inc
NYSE:ABBV
25.9
US
Amgen Inc
NASDAQ:AMGN
18.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -88.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3
AU
CSL Ltd
ASX:CSL
45.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -548.7

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A